Global Oligonucleotide CDMO Market Revenue Grows at a CAGR of 14.86% .

Straits Research released its highly anticipated report, “Global Oligonucleotide CDMO Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 1042.20 million in 2025 and is anticipated to grow till USD 3614.46 million by 2034, growing at a CAGR of 14.86% from 2026-2034.

Market Dynamics

The oligonucleotide CDMO market is driven by the expanding clinical and commercial pipeline of RNA-based therapeutics that require complex synthesis, purification, and regulatory-compliant manufacturing capabilities. Pharmaceutical and biotechnology companies increasingly rely on external CDMO partners to manage chemically modified backbones, conjugation chemistries, and stringent quality control requirements associated with antisense oligonucleotides and small interfering RNA programs. This outsourcing trend supports efficient progression from early development to commercial scale production while allowing sponsors to focus internal resources on discovery and clinical strategy. However, the market faces a restraint in the form of high technical complexity and capacity constraints associated with large-scale oligonucleotide manufacturing. Limited availability of specialized equipment, skilled personnel, and validated analytical methods creates challenges in meeting growing demand, particularly for late-stage and commercial supply. Extended lead times for facility expansion and process validation further restrict rapid scalability for CDMO providers. Despite this, the market presents a strong opportunity through rising demand for integrated end-to-end service models that combine process development, clinical manufacturing, and commercial supply within a single partnership. Sponsors increasingly prefer long-term CDMO relationships that support lifecycle management, regulatory documentation, and post-approval manufacturing continuity. Expansion of oligonucleotide applications beyond rare diseases into cardiometabolic, oncology, and inflammatory indications further broadens the addressable market for CDMO services. Additionally, growing interest in diversified supply chains and geographic manufacturing redundancy supports investment in new facilities and regional expansion, positioning the oligonucleotide CDMO market for sustained growth through comprehensive service offerings aligned with evolving therapeutic pipelines.

Market Highlights

• Service Type: Based on Service Type, contract development is anticipated to register the fastest CAGR of 15.23% during the forecast period.
• Type: Based on Type, antisense oligonucleotides dominated the market with a revenue share of 36.78%.
• Application: Based on Application, the therapeutic segment dominated the market with a revenue share of 39.85% in 2025.
• End Use: Based on End Use, pharmaceutical and biopharmaceutical companies dominated the market with a revenue share of 35.67%.
• Regional Insights: North America held a dominant share of the global market, accounting for 37.54% in 2025.

Market Segments

1. By Service Type (2026-2034)
   1. Contract Manufacturing
   2. Contract Development
2. By Type (2026-2034)
   1. Antisense Oligonucleotides
   2. Small Interfering RNA
   3. Other Oligonucleotides
3. By Application (2026-2034)
   1. Therapeutic
   2. Research
   3. Diagnostic
4. By End Use (2026-2034)
   1. Pharmaceutical and Biopharmaceutical Companies
   2. Diagnostic Companies
   3. Others